SCHEMBL4833553

SCHEMBL4833553

COc1ccc(N2C(N)=c3ccoc3=NC2C(=O)Nc2ccccc2O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ GAA P10253 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ PKM P14618 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ LMNA P02545 3/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ HSD11B1 P28845 1/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ ABCG2 Q9UNQ0 2/20 0.35
▸ HDAC3 O15379 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC7 Q8WUI4 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826594 0.89 KMT2A (0.44) MAPTKMT2AGAARAB9AMEN1
SCHEMBL4831333 0.88 CYP2C19 (0.39) MAPTKMT2AGAARAB9AMEN1
SCHEMBL4836739 0.86 POLB (0.40) MAPTKMT2ARAB9AMEN1PKM
SCHEMBL4834037 0.84 KMT2A (0.39) MAPTKMT2AGAARAB9AMEN1
SCHEMBL4825859 0.82 MAPT (0.44) MAPTKMT2AMEN1PKMALDH1A1
SCHEMBL4833975 0.82 KDM4E (0.46) KMT2ARAB9APKMALDH1A1HPGD
SCHEMBL4825844 0.82 POLB (0.39) MAPTGAARAB9AALDH1A1SMN1; SMN2
SCHEMBL4833804 0.81 POLB (0.42) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL4835760 0.81 L3MBTL1 (0.38) MAPTKMT2AGAARAB9AALDH1A1
SCHEMBL4831357 0.81 ALDH1A1 (0.38) KMT2AGAARAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885KMT2A 324/4885GAA 3329/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885KMT2A 334/4885GAA 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback